Precision Medicine Podcast · Trapelo

Liquid Biopsy for Precision Medicine: What’s Actionable Now and What’s Next

·29 min·1 clip
Early detection can lead to radical surgery, radical radiotherapy, or even early treatment.
Season 7 begins with the Precision Medicine Podcast returning to one of the most important and fast-moving areas in cancer diagnostics. The episode presents liquid biopsy as a technology reshaping the diagnostic moment, while also making clear how much still needs to happen before it is fully built into routine care. The hosts connect that discussion to the series theme of bringing precision medicine to everyone and to the larger question of equity, since the information available at diagnosis can shape what care follows. A prior episode with Dr. Kashyap Patel is used as a useful anchor for listeners who are catching up. From there, the conversation turns to the practical question of how liquid biopsy can be standardized and used well. The guests focus on the gap between scientific promise and consistent clinical use. Standardization comes up early as a central need. The discussion points to preanalytical conditions as one area that needs clearer agreement. It also references groups such as BloodPak, work from ISLB, and the International Liquid Biopsy Standardization Alliance as part of that effort. That work is described as covering preanalytical and technical questions that shape how results should be interpreted. Clinical trials are another major thread. The guests discuss the need to standardize endpoints so liquid biopsy can be used in ways that matter in both research and practice. Sensitivity and specificity are also part of the frame, tied directly to whether the test reflects what is really happening in the cancer process. Reimbursement sits alongside the science as a real-world barrier. The episode makes clear that implementation is not only about the assay itself, but also about whether systems can line up around it. The result is a conversation that feels informed, measured, and highly practical. It is especially useful for listeners who want to understand how a promising diagnostic becomes part of routine cancer care. It also keeps the focus on translation rather than hype, treating liquid biopsy as a tool whose value depends on how carefully the field defines and uses it.

As heard by us

A careful look at how liquid biopsy moves from promise toward standardized clinical use.

This episode treats liquid biopsy as an active clinical problem, not just an emerging technology, and stays centered on how precision oncology reaches patients.

Read the full review in PlayNext →

Why you'd press play

A practical look at liquid biopsy's path from promise to clinical standardization.

Read the full recommendation in PlayNext →
Listen to the show on